The
NSAID (non-steroidal anti-inflammatory
drug)
indomethacin, a cyclo-oxygenase-1 and -2 inhibitor with anti-inflammatory and
analgesic properties, is known to possess anticancer activity against CRC (
colorectal cancer) and other
malignancies in humans; however, the mechanism underlying the anticancer action remains elusive. In the present study we show that
indomethacin selectively activates the dsRNA (
double-stranded RNA)-dependent
protein kinase PKR in a
cyclo-oxygenase-independent manner, causing rapid phosphorylation of eIF2α (the α-subunit of eukaryotic translation
initiation factor 2) and inhibiting
protein synthesis in
colorectal carcinoma and other types of
cancer cells. The PKR-mediated translational block was followed by inhibition of CRC cell proliferation and apoptosis induction.
Indomethacin did not affect the activity of the eIF2α
kinases PERK (PKR-like endoplasmic reticulum-resident
kinase), GCN2 (general control non-derepressible-2) and HRI (
haem-regulated inhibitor
kinase), and induced eIF2α phosphorylation in PERK-knockout and GCN2-knockout cells, but not in PKR-knockout cells or in human PKR-silenced CRC cells, identifying PKR as a selective target for
indomethacin-induced translational inhibition. The fact that
indomethacin induced PKR activity in vitro, an effect reversed by the PKR inhibitor
2-aminopurine, suggests a direct effect of the
drug in
kinase activation. The results of the present study identify PKR as a novel target of
indomethacin, suggesting new scenarios on the molecular mechanisms underlying the pleiotropic activity of this traditional
NSAID.